دورية أكاديمية
أعرض في EDS

Lower Expression of TWEAK is Associated with Poor Survival and Dysregulate TIICs in Lung Adenocarcinoma.

التفاصيل البيبلوغرافية
العنوان: Lower Expression of TWEAK is Associated with Poor Survival and Dysregulate TIICs in Lung Adenocarcinoma.
المؤلفون: He Z; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.; Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University Changsha, Hunan 410013, China.; NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.; Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan 410011, China., Wang S; Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China., Wu J; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China., Xie Y; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410008, China., Li B; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
المصدر: Disease markers [Dis Markers] 2022 Jun 06; Vol. 2022, pp. 8661423. Date of Electronic Publication: 2022 Jun 06 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 8604127 Publication Model: eCollection Cited Medium: Internet ISSN: 1875-8630 (Electronic) Linking ISSN: 02780240 NLM ISO Abbreviation: Dis Markers Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : New York, NY : Hindawi Pub. Corp.
Original Publication: Chichester ; New York : Wiley, c1983-
مواضيع طبية MeSH: Adenocarcinoma of Lung*/genetics , Adenocarcinoma of Lung*/pathology , Cytokine TWEAK*/genetics , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lymphocytes, Tumor-Infiltrating*, Humans ; Receptors, Tumor Necrosis Factor/genetics ; Receptors, Tumor Necrosis Factor/metabolism ; TWEAK Receptor/genetics ; Tumor Necrosis Factors/genetics
مستخلص: Background: Lung cancer remains the leading cause of cancer death worldwide, and the most subtype is lung adenocarcinoma (LUAD). Tumor-infiltrating immune cells (TIICs) greatly impact the prognosis of LUAD. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), signal via its receptor fibroblast growth factor-inducible 14 (Fn14), dysregulates immune cell recruitment within tumor environment, thus promoting the progression of autoimmune diseases and cancer. We aimed to explore its role in LUAD.
Methods: The expression level of TWEAK was explored in Tumor Immune Estimation Resource 2.0 (TIMER2.0) and Oncomine databases. The Tumor Immune Dysfunction and Exclusion (TIDE) and Lung Cancer Explorer (LCE) databases were applied to evaluate the survival in correlation to TWEAK expression. TIICs were assessed with TIMER2.0 and TIDE datasets. The expression of TWEAK protein was detected in LUAD cell lines and also in tissue samples from LUAD patients via western blotting or combination with immunochemistry.
Results: Our results showed that TWEAK was downregulated in LUAD tumors compared to normal tissues in TIMER2.0, Oncomine, cell lines, and clinical specimens. Poor survival was uncovered in lower TWEAK expression of LUAD patients in LCE (meta - HR = 0.84 [95% CI, 0.76-0.92]) and TCGA (Continuous Z = -1.97, p = 0.0486) and GSE13213@PRECOG (Continuous Z = -4.25, p = 2.12e - 5) in TIDE. Multiple tumor-infiltrating immune cells (TIICs) were found closely correlated with TWEAK expression in LUAD, especially hematopoietic stem cell (Rho = 0.505, p = 2.78e - 33), common lymphoid progenitor (Rho = -0.504, p = 3.79e - 33), and myeloid-derived suppressor cells (MDSCs) (Rho = -0.615, p = 1.36e - 52).
Conclusion: Lower level of TWEAK was linked with poor survival and aberrant recruitment and phenotype of TIICs in LUAD, which might motivate immune escape and weaken the effects of immunotherapy.
Competing Interests: The authors report no conflicts of interest in this work.
(Copyright © 2022 Zhengxi He et al.)
References: Clin Ther. 2013 Aug;35(8):1137-49. (PMID: 23928094)
PLoS One. 2011 Jan 07;6(1):e14497. (PMID: 21249128)
Immunology. 2016 May;148(1):70-82. (PMID: 27040357)
Biomaterials. 2015 Feb;42:42-51. (PMID: 25542792)
Neuro Oncol. 2018 Sep 3;20(10):1321-1330. (PMID: 29897522)
J Immunol. 2010 Aug 1;185(3):1593-605. (PMID: 20610643)
Mucosal Immunol. 2013 Nov;6(6):1131-42. (PMID: 23462911)
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. (PMID: 30476243)
Oncotarget. 2015 Apr 30;6(12):10592-603. (PMID: 25871392)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Mol Cancer Ther. 2014 Nov;13(11):2688-705. (PMID: 25239934)
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. (PMID: 32442275)
J Biol Chem. 2011 Jun 17;286(24):21546-54. (PMID: 21525013)
Clin Cancer Res. 2015 Jan 15;21(2):258-66. (PMID: 25388164)
Am J Pathol. 2003 Apr;162(4):1313-21. (PMID: 12651623)
MAbs. 2011 Jul-Aug;3(4):362-75. (PMID: 21697654)
J Invest Dermatol. 2013 Apr;133(4):1052-62. (PMID: 23190886)
PLoS One. 2014 Nov 06;9(11):e104227. (PMID: 25375638)
Mol Cancer Res. 2015 Mar;13(3):575-83. (PMID: 25392346)
Cancer Res. 2017 Nov 1;77(21):e108-e110. (PMID: 29092952)
PLoS One. 2013 Oct 10;8(10):e77050. (PMID: 24130833)
Cytokine Growth Factor Rev. 2014 Apr;25(2):215-25. (PMID: 24444596)
Oncogene. 2019 Apr;38(14):2551-2564. (PMID: 30532070)
Cell. 2005 Dec 2;123(5):931-44. (PMID: 16325585)
J Cell Physiol. 2021 May;236(5):3304-3316. (PMID: 33000480)
Oncol Rep. 2018 Feb;39(2):573-581. (PMID: 29251323)
Cancer Biol Ther. 2012 Jul;13(9):812-21. (PMID: 22669574)
Cancer Res. 2013 Jul 15;73(14):4439-50. (PMID: 23722548)
Respir Res. 2015 Apr 08;16:48. (PMID: 25890309)
Gynecol Oncol. 2011 Oct;123(1):123-8. (PMID: 21788066)
Neoplasia. 2007 Feb;9(2):166-80. (PMID: 17356713)
J Immunol. 2000 Mar 15;164(6):2897-904. (PMID: 10706675)
Front Biosci. 2007 Jan 01;12:2761-71. (PMID: 17127278)
Clin Exp Metastasis. 2014 Aug;31(6):613-23. (PMID: 24710956)
Nat Med. 2018 Oct;24(10):1550-1558. (PMID: 30127393)
Redox Biol. 2019 Jul;25:101174. (PMID: 30917934)
Clin Cancer Res. 2013 Oct 15;19(20):5686-98. (PMID: 23974006)
J Biol Chem. 2010 Jun 4;285(23):17432-41. (PMID: 20385556)
Results Probl Cell Differ. 2009;49:145-60. (PMID: 19513634)
J Signal Transduct. 2012;2012:376470. (PMID: 22649723)
Biomed Pharmacother. 2017 Nov;95:55-61. (PMID: 28826097)
J Exp Clin Cancer Res. 2019 Apr 25;38(1):176. (PMID: 31023317)
Immunol Res. 2016 Feb;64(1):44-50. (PMID: 26659091)
Mol Cancer Ther. 2011 Jul;10(7):1276-88. (PMID: 21586630)
Cancer Immunol Immunother. 2019 May;68(5):835-847. (PMID: 30406374)
Biochem Biophys Res Commun. 2005 Jun 3;331(2):384-90. (PMID: 15850771)
Cancer Lett. 2010 Aug 1;294(1):91-100. (PMID: 20189297)
Clin Cancer Res. 2016 Feb 15;22(4):858-67. (PMID: 26446946)
Tumour Biol. 2017 Jun;39(6):1010428317714624. (PMID: 28639899)
Med Sci Monit. 2018 Mar 03;24:1282-1294. (PMID: 29500337)
Genome Biol. 2016 Aug 22;17(1):174. (PMID: 27549193)
Eur Arch Otorhinolaryngol. 2015 Jul;272(7):1733-41. (PMID: 24858806)
Nat Commun. 2017 May 22;8:15395. (PMID: 28530223)
Med Sci Monit. 2020 Mar 30;26:e920537. (PMID: 32225128)
Nat Commun. 2015 Aug 05;6:7792. (PMID: 26242746)
MAbs. 2014 Jan-Feb;6(1):297-308. (PMID: 24135629)
J Immunol Res. 2017;2017:5737159. (PMID: 29075649)
Cell Physiol Biochem. 2017;43(2):579-588. (PMID: 28934756)
J Biol Chem. 2006 May 19;281(20):13964-71. (PMID: 16547002)
Mol Cancer Res. 2014 Apr;12(4):550-9. (PMID: 24469836)
Trends Pharmacol Sci. 2019 Jan;40(1):4-7. (PMID: 30527590)
المشرفين على المادة: 0 (Cytokine TWEAK)
0 (Receptors, Tumor Necrosis Factor)
0 (TNFSF12 protein, human)
0 (TWEAK Receptor)
0 (Tumor Necrosis Factors)
تواريخ الأحداث: Date Created: 20220616 Date Completed: 20220617 Latest Revision: 20220716
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9192298
DOI: 10.1155/2022/8661423
PMID: 35707713
قاعدة البيانات: MEDLINE
الوصف
تدمد:1875-8630
DOI:10.1155/2022/8661423